Coenzyme Q10
- Generic Name
- Coenzyme Q10
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C59H90O4
- CAS Number
- 303-98-0
- Unique Ingredient Identifier
- EJ27X76M46
- Background
Ubidecarenone, also called coenzyme Q10, is a 1,4-benzoquinone. From its name (Q10), the Q refers to the constitutive quinone group, and 10 is related to the number of isoprenyl subunits in its tail. It is a powerful antioxidant, a lipid-soluble and essential cofactor in mitochondrial oxidative phosphorylation. The ubidecarenone is the coenzyme destined for ...
- Indication
The diet supplements containing ubidecarenone are indicated, as stated in the product label, to assist individuals with cardiovascular complaints including congestive heart failure and systolic hypertension. In the product, ubidecarenone is used to increase the cardiac input as well as for the prevention of several other diseases like Parkinson, fibromyalgia...
- Associated Conditions
- Migraine
- Associated Therapies
- -
Study About Safety and Efficacy of Coenzyme Q10 in Progressive Supranuclear Palsy
- First Posted Date
- 2006-05-24
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- German Parkinson Study Group (GPS)
- Target Recruit Count
- 20
- Registration Number
- NCT00328874
- Locations
- 🇩🇪
Neurologische Klinik der Philipps-Universität Marburg, Marburg, Hessen, Germany
Mitochondrial Dysfunction in the Pathophysiology and Treatment of Bipolar Disorder
- Conditions
- First Posted Date
- 2006-05-19
- Last Posted Date
- 2011-11-23
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Registration Number
- NCT00327756
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Clinical Trial of High Dose CoQ10 in ALS
- Conditions
- Interventions
- First Posted Date
- 2005-10-25
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 185
- Registration Number
- NCT00243932
- Locations
- 🇺🇸
Columbia Presbyterian Medical Center, The Neurological Institute, New York, New York, United States
🇺🇸Washington University in St. Louis School of Medicine, Department of Neurology, Saint Louis, Missouri, United States
🇺🇸University of Kentucky, Dept of Neurology, College of Medicine, Lexington, Kentucky, United States
NINDS Parkinson's Disease Neuroprotection Trial of CoQ10 and GPI 1485
- Conditions
- First Posted Date
- 2004-01-27
- Last Posted Date
- 2012-11-02
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 195
- Registration Number
- NCT00076492
- Locations
- 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
An Open-label Pilot Study of Coenzyme Q10 in Steroid-Treated Duchenne Muscular Dystrophy
- Conditions
- First Posted Date
- 2002-04-09
- Last Posted Date
- 2010-11-16
- Target Recruit Count
- 15
- Registration Number
- NCT00033189
- Locations
- 🇺🇸
Washington University-St. Louis, St. Louis, Missouri, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
Parkinson's Disease Treatment With Coenzyme Q10
- Conditions
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.